Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission

Inclusion Criteria: * All adults with first remission AML including those with prior myelodysplasia (MDS)/AML, therapy-related AML, AML with trilineage dysplasia (AML-TLD), and AML with adverse cytogenetics * History of histopathologically documented AML that is currently in first remission with the presence of 5% or less blasts by morphology and/or flow cytometry from a bone marrow aspirate and/or biopsy obtained within 14 days of enrollment * Patients must start therapy between 3-8 weeks after receiving their last prior therapy (either induction therapy or consolidation therapy) * Patients may receive up to 4 courses of remission consolidation therapy (e.g., cytarabine) prior to enrollment * Normal kidney and liver function with serum creatinine =\< 2.0 mg/dl * Total bilirubin =\< 1.5 upper limit of normal (ULN) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 x ULN * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 * Male subjects, even if surgically sterilized (i.e., status postvasectomy) must agree to 1 of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourse * Female subject is either postmenopausal for at least 1 year before the screening visit, is surgically sterilized or if they are of childbearing potential, agree to practice 2 effective methods of contra…